Size | Price | |
---|---|---|
1mg | ||
5mg | ||
10mg | ||
Other Sizes |
ln Vitro |
Adintrevimab has had its half-life extended by altering its Fc fragment region. In the SARS-CoV-2 spike glycoprotein receptor binding domain, anintrevimab binds to a distinct epitope that is highly conserved across sarbecoviruses and partially overlaps with the binding site of the angiotensin-converting enzyme 2. Alpha, Beta, Gamma, and Delta strains of SARS-CoV-2, as well as other SARS-like viruses, have all been shown to be effectively neutralized by adintrevimab when tested in vitro. In vitro activity of adintrevimab against Omicron BA.1/BA.1.1 has been observed to be diminished, but it exhibits no activity against BA.2, BA.3, BA.4, and BA.5 [1].
|
---|---|
ln Vivo |
In a dose-dependent manner, adintrevimab (9.25, 55, 333, or 2,000 μg; intraperitoneal; once) protects against SARS-CoV-2/WA1/2020 infection [1]. In a dose-dependent manner, adintrevimab (5–25 mg/kg; IV; once) protects against SARS-CoV-2/WA1/2020 infection [1].
|
Animal Protocol |
Animal/Disease Models: Syrian golden hamsters (5-6weeks old females; 75-125 g) infected with SARS-CoV-2/WA1/2020[1].
Doses: 9.25, 55, 333, or 2,000 μg (average range: 0.1 to 20 mg/kg) Route of Administration: intraperitoneal (ip)injection; single dose Experimental Results: demonstrated significant reduction in lung viral load and virus-induced lung pathology. Animal/Disease Models: Rhesus macaques (5.6-8.8 years old; 6 females [4.4-6.3 kg] and 6 males [6.1-8.5 kg]) infected with SARS-CoV-2/WA1/2020[1]. Doses: 5 mg/kg, 25 mg/kg Route of Administration: intravenous (iv)injection; single dose Experimental Results: diminished pulmonary inflammation. |
References |
[1]. Elizabeth E Zumbrun, et al. Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19. Antimicrob Agents Chemother. 2022 Dec 15;e0135322.
|
CAS # |
2516243-54-0
|
---|---|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.